Skip to main content

Table 1 Systemic lupus erythematosus patient characteristics and disease parameters

From: Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs

Total SLE patients

192

Sex (female/male)

178/14

Age (mean ± sd)

47.24 ± 14.63

Age at diagnosis (mean ± sd)

33.88 ± 14.53

Disease duration (mean ± sd)

13.16 ± 7.83

Clinical manifestations, n (%)

 

   Malar rash

102 (53.1)

   Discoid lesions

38 (19.8)

   Subacute cutaneous lesions

33 (17.2)

   Photosensitivity

99 (51.6)

   Oral ulcers

63 (32.8)

   Arthritis

139 (72.4)

   Serositis

48 (25.0)

   Renal disorder

56 (29.2)

   Neurological disorder

15 (7.8)

   Hematological disorder

111 (57.8)

Treatment, n (%)

 

   None/NSAIDS

23 (12.0)

   Antimalarials

114 (59.4)

   Corticosteroids

126 (65.6)

   Immunosuppressive drugsa

41 (21.4)

  1. aMethotrexate, azathioprine, cyclophosphamide, cyclosporine A or mycophenolate mophetil. NSAIDS, nonsteroidal anti-inflammatory drugs; SD, standard deviation; SLE, systemic lupus erythematosus.